, Leishmaniasis: Current Status of Vaccine Development, Clinical Microbiology Reviews, vol.14, issue.2, pp.229-243, 2001.
DOI : 10.1128/CMR.14.2.229-243.2001
, Vaccines against Leishmania New generation vaccines, Informa Healthcare, pp.790-807, 2010.
, Vaccines for leishmaniasis in the fore coming 25 years, Vaccine, vol.26, issue.14, pp.1709-1724, 2008.
DOI : 10.1016/j.vaccine.2008.01.023
, DNA vaccines: a rational design against parasitic diseases, Expert Review of Vaccines, vol.9, issue.2, pp.175-91, 2010.
DOI : 10.1586/erv.09.158
, Polymeric Materials for Gene Delivery and DNA Vaccination, Advanced Materials, vol.82, issue.8, pp.1-21, 2008.
DOI : 10.1002/adma.200801478
, Lipid based particulate formulations for the delivery of antigen, Immunology and Cell Biology, vol.45, issue.2, pp.97-105, 2005.
DOI : 10.1016/S0169-409X(98)00013-1
, Solid lipid nanoparticles (SLN) for controlled drug delivery ?????? a review of the state of the art, European Journal of Pharmaceutics and Biopharmaceutics, vol.50, issue.1, pp.161-177, 2000.
DOI : 10.1016/S0939-6411(00)00087-4
, Lipid nanoparticles for parenteral delivery of actives, European Journal of Pharmaceutics and Biopharmaceutics, vol.71, issue.2, pp.161-172, 2009.
DOI : 10.1016/j.ejpb.2008.09.003
, Proteinases of trypanosomes and Leishmania. In: Trypanosomiasis and Leishmaniasis: Biology and Control, p.177, 1997.
, Parasite cysteine proteinases, Perspectives in drug discovery and design ESCOM Science publisher. 99 p, 1996.
DOI : 10.1007/BF02174048
, Leishmania major:Comparison of the Cathepsin L- and B-like Cysteine Protease Genes with Those of Other Trypanosomatids, Experimental Parasitology, vol.85, issue.1, pp.63-76, 1997.
DOI : 10.1006/expr.1996.4116
, Leishmania Cysteine Proteinases: From Gene to Subunit Vaccine, Current Genomics, vol.4, issue.3, pp.253-61, 2003.
DOI : 10.2174/1389202033490439
, Leishmania infantum: Prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice, Experimental Parasitology, vol.118, issue.3, pp.393-401, 2008.
DOI : 10.1016/j.exppara.2007.10.004
URL : https://hal.archives-ouvertes.fr/pasteur-00796762
, A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major, Vaccine, vol.19, issue.25-26, pp.3369-75, 2001.
DOI : 10.1016/S0264-410X(01)00081-0
, Chemical adjuvants for plasmid DNA vaccines, Vaccine, vol.25, issue.19, pp.3731-3741, 2007.
DOI : 10.1016/j.vaccine.2007.01.120
, A review of adjuvants for Leishmania vaccine candidates, Journal of Biomedical Research, vol.24, issue.1, pp.16-25, 2010.
DOI : 10.1016/S1674-8301(10)60004-8
, Cationic Solid Lipid Nanoparticles Loaded by Cystein Proteinase Genes as a Novel anti-Leishmaniasis DNA Vaccine Delivery System: Characterization and in vitro Evaluations, Journal of Pharmacy & Pharmaceutical Sciences, vol.13, issue.3, pp.320-335, 2010.
DOI : 10.18433/J3R30T
URL : https://hal.archives-ouvertes.fr/pasteur-00786930
, Transgenic Leishmania donovani clinical isolates expressing green fluorescent protein constitutively for rapid and reliable ex vivo drug screening, Journal of Antimicrobial Chemotherapy, vol.64, issue.2, pp.370-374, 2009.
DOI : 10.1093/jac/dkp206
, IL-10 leads to a higher parasite persistence in a resistant mouse model of Leishmania major infection, Parasitology International, vol.51, issue.4, pp.367-379, 2002.
DOI : 10.1016/S1383-5769(02)00039-9
, Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice, Antimicrobial Agents and Chemotherapy, vol.39, issue.9, pp.2167-2168, 1995.
DOI : 10.1128/AAC.39.9.2167
, Second-generation vaccines against leishmaniasis, Trends in Parasitology, vol.21, issue.5, pp.244-249, 2005.
DOI : 10.1016/j.pt.2005.03.006
, New horizons in adjuvants for vaccine development, Trends in Immunology, vol.30, issue.1, pp.23-32, 2009.
DOI : 10.1016/j.it.2008.09.006
, Real-Time In Vivo Green Fluorescent Protein Imaging of a Murine Leishmaniasis Model as a New Tool for Leishmania Vaccine and Drug Discovery, Clinical and Vaccine Immunology, vol.15, issue.12, pp.1764-1770, 2008.
DOI : 10.1128/CVI.00270-08
, Fluorescent Leishmania species: Development of stable GFP expression and its application for in vitro and in vivo studies, Experimental Parasitology, vol.127, issue.3, pp.637-645, 2011.
DOI : 10.1016/j.exppara.2010.12.006
URL : https://hal.archives-ouvertes.fr/pasteur-00786977
, Flagellin Fusion Proteins as Adjuvants or Vaccines Induce Specific Immune Responses, Infection and Immunity, vol.72, issue.5, pp.2810-2816, 2004.
DOI : 10.1128/IAI.72.5.2810-2816.2004
, Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8+ T lymphocyte activation, Vaccine, vol.20, issue.19-20, pp.24-39, 2002.
DOI : 10.1016/S0264-410X(02)00189-5
, Cellular immunology and immune regulation: Lipid Vesicle Size Determines the Th1 or Th2 Response to Entrapped Antigen, J Immunol, vol.161, pp.4000-4007, 1998.
, Contribution of CpG motifs to the immunogenicity of DNA vaccines, J Immunol, vol.158, pp.3635-3639, 1997.
, Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy, Advanced Drug Delivery Reviews, vol.61, issue.3, pp.233-242, 2009.
DOI : 10.1016/j.addr.2008.12.014
, Cholesterol domains in cationic lipid/DNA complexes improve transfection, Biochimica et Biophysica Acta (BBA) - Biomembranes, vol.1778, issue.10, pp.2177-2181, 2008.
DOI : 10.1016/j.bbamem.2008.04.009
, Stimulation of Triglyceride-Rich Lipoprotein Secretion by Polysorbate 80: In Vitro and in Vivo Correlation Using Caco-2 Cells and a Cannulated Rat Intestinal Lymphatic Model, Pharmaceutical Research, vol.207, issue.12, pp.2320-2326, 2004.
DOI : 10.1007/s11095-004-7684-4
, Immunostimulation of dendritic cells by cationic liposomes, Molecular Membrane Biology, vol.160, issue.5, pp.385-395, 2006.
DOI : 10.1126/science.278.5343.1612